|
Today's Headlines
Soon after FDA expressed concerns over the higher dosages and safety profile, including daytime drowsiness, of the proposed sleep agent known as suvorexant (Merck), the Agency’s Peripheral and Central Nervous System Drugs Advisory Committee voted 13-3, with 1 abstention, in favor of the safety of 2 proposed starting doses of suvorexant — 15 mg in patients over the age of 65 and 20 mg in patients under the age of 65. » Full article
|
|
Actavis Inc. announced May 20 its plans to acquire Warner Chilcott in a stock transaction deal, which is worth approximately $8.5 billion. The merger is expected to create a global specialty pharmaceutical company serving the women’s health, gastroenterology, urology, and dermatology therapeutic sectors, according to a joint company release. » Full article
|
|
Senators from the Health, Education, Labor and Pensions Committee have introduced a revised version of its draft compounding bill to help improve the safety of compounded human and animal drugs, following feedback earlier this month from stakeholders, including the American Society of Health-System Pharmacists. » Full article
|
|
Patients with multiple cardiovascular risk factors are not able to reduce their mortality risk from CV causes with daily n-3 polyunsaturated fatty acid intake, according to a long-term Italian study published May 9 in the New England Journal of Medicine.
» Full article
|
Continuing Education
Welcome to our CPE series: Pain Management Considerations for Medication Therapy Management, which has been designed for pharmacists who take care of patients who need pain relief. You can earn up to 10 credits from April 2013 to August 2013 with 5 monthly knowledge-based activities and 2 credits from September 2013 to October 2013 with 2 monthly interactive online case studies.
The May activity covers pharmacology and therapeutics of pain medications, focusing on non-opioid analgesics.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in.
Announcement: Welcome to the new user registration process. This new process requires all pharmacists and pharmacy technicians to provide
or update their NABP e-Profile ID in order to electronically keep track of CPE credits from ACPE-accredited providers. If you have not done so, you can obtain your NABP e-Profile ID now at
www.MyCPEmonitor.net. This profile will enable you to have one login
for all the NABP programs and services you will need throughout your career.
|
|
EDITOR'S PICK
An examination of people’s behaviors as they relate to drug use in the 20th century has shown that people will expend a large amount of energy to acquire any agent that has the ability to alter their minds, bodies, or behaviors in order to achieve a euphoric effect. It is with prolonged use of a substance that addiction or tolerance can develop, which can lead to impairments in social, academic, or occupational functioning. » Full article
|
|
|
SURVEY
— FDA should require all existing opioids to be reformulated in this fashion
— FDA should require only new opioid introductions (brand and generic) to be abuse-deterrant
— FDA should require only new ‘branded’ opioids to be abuse-deterrant in nature
Click Here to let us know.
|
|
Like
Tweet
